Abatacept now approved for rheumatoid arthritis after failure of conventional DMARDs

Following a review, NICE have overturned their previous negative decision for abatacept (Orencia) following the introduction of a patient access scheme.

This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY
This new guidance brings the drug in line with other anti-TNF drugs licensed for the treatment of rheumatoid arthritis (pictured) that have been approved by NICE for NHS use | SCIENCE PHOTO LIBRARY

Previously, abatacept was only approved for use in rheumatoid arthritis after the failure of a TNF inhibitor. Now it may also be used in adults whose disease has responded inadequately to 2 conventional disease-modifying anti-rheumatic drugs (DMARDs), including methotrexate, provided the manufacturer supplies abatacept with the discount agreed in the patient access scheme.

View Orencia drug record

NICE guidance on abatacept in rheumatoid arthritis after failure of conventional DMARDS

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases